Kiritsy Christopher P's Form 4 filing
Palvella Therapeutics, Inc. (PVLA) · filed Sep 4, 2026
- Accession no.
- 0001104659-26-105494
- Filed
- Sep 4, 2026, 4:05 PM ET
- Trade date
- Sep 2, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $49.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kiritsy Christopher PCIK 0001261156 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | MOption exerciseAcquired | +313 | $127.20F1 | +$39,813.6 | 563 | Direct | |
| Sep 2, 2026 | Common Stock | SSaleDisposed | −313 | $157.00 | −$49,141 | 250 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Common Stock | MOption exerciseDisposed | −313 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported number of shares has been adjusted to reflect the impact of the Issuer's 1-for-80 reverse stock split, which became effective on April 23, 2024.
Referenced by the price of 1 transaction in Table I.